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Introduction
The incidence of complete Achilles tendon rupture is 18 per 100 000 patient-years1 and is usually
diagnosed clinically by GPs. The extent of clinical misdiagnosis is unknown in Norway, but may be
high.2 This is important as delayed treatment has unfavourable consequences.1,3 We report how a
GP, with no clinical ultrasound experience, recorded images with a pocket-sized ultrasound device
(PSUD) under supervision to confirm a complete Achilles tendon rupture. This could present a new
indication for GP ultrasound.
Case report
A 36-year-old man experienced acute pain above the right heel accompanied by an audible snap
while sprinting. He immediately had difficulty walking and 3 hours later consulted an on-call GP. Pos-
terior ankle swelling with a tender depression 3 cm proximal to the calcaneum was found. Active
plantar flexion against resistance was weak and Simmonds–Thompson test was ‘partially positive’ on
applying a strong calf-squeeze. Based on these findings, calf muscle rupture was diagnosed as the
Achilles tendon was thought to be intact. The patient was advised to elevate the foot and wait 2
weeks for improvement. Two days later a second GP, who was aware of a history of an audible snap,
considered complete tendon rupture and reexamined the patient. Findings included an absent right
heel raise due to weakness, minimal active plantar flexion against gravity and lying prone, significant
right ankle swelling without bruising, and an altered angle of declination. Palpation elicited no ankle
bony tenderness, yet a painful gap was identified 6 cm proximal from the calcaneal attachment,
along the line of the Achilles tendon. Simmonds–Thompson’s test was clearly positive. The positive
Simmond’s triad indicated a clinical diagnosis of complete rupture of the Achilles tendon.
A 3.4–8 MHz linear array probe PSUD (VScan dual probe, GE Healthcare), set at a depth of
3.5 cm, was used under the supervision of a rheumatologist experienced in ultrasound. The tendon
was enlarged from 1 cm to 6 cm above the calcaneal insertion, where a clear gap was seen
(Figure 1). Two hours later a radiologist-performed ultrasound (LOGIQ E9, GE Healthcare)
and reported an enlarged distal tendon and a complete rupture at 5–6 cm from the calcaneal attach-
ment, creating a 2.7 cm blood-filled gap (Figure 2). Surgical exploration 8 days post-injury found a
complete Achilles tendon rupture ‘5–10 cm above the ankle joint’.
Discussion
Tromsø Hospital serves a large area with a population of approximately 160 000. Between 2010–
2014 an average of 21 patients per year were referred by their GP for suspected Achilles rupture.
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Introduction
Last summer our small medical team visit the Calais ’Jungle’. Since that time muc has hanged
and the camp is being demolished and by the time this article is read, it will probably be long gone.
Some you gsters are finally being brought to the UK under the ’Dubs’ amendment. H wever, once
this camp is clear d it will not solve the ongoing flight of refugees from war torn areas: other camps
are already appearing.
July 2016
A young Afghan man caught his finger on a sharp point while trying to cross a barbed wire fence.
The finger was partially degloved. He attended the local hospital, where they placed a few sutures,
but now, 2 weeks later, the skin is necrotic and the underlying tissue looks infected. He is in danger
of losing his finger.
A middle-aged Sudanese man has been having rigors and is generally unwell. He says it is similar
to when he last had malaria.
A young Ukrainian woman complains of lower back pain and urinary frequency.
Th paths of these three people may never have crossed; yet here they are, denizens of the Calais
Jungle. They turn up to a makeshift primary care ‘clinic’ that we set up in the heart of the unofficial
refugee camp on weekend in July 2016.
With only basic medical supplies, we are immediately ch llenged by what we see. How can w
arrange sec dary care for the young Afghan in danger of losing his finger? We try to persuade him
to return to the original local hospital, but is reluctant. It was not a good experience for him t
first time round.
With the other two patients, it is easier. They can attend the Salam clinic run by a loc l association
during w ekdays. Later, we receive word that malaria has been confirmed in our Su anese patient.
More people arrive, presenting with scabies, rat bites, tinea, chest infections, and wheezing from
inhaling smok from fires lit to cook keep warm in their t nts t night. We examin a severely
malnourish d 2-year-old boy. We meet everal of the ca ’s 600 unaccompanied children, at grave
risk of sexual exploitation. We learn that there i inadequate safeguarding in place to prot ct them.
A young Eritrean man comes i worried about his eye. H has sustained direct ocular trauma from a
rubber bullet, and will never see normally again out of that eye. We see aematomas from olice
batons, and hear about children being exposed to tear gas again and again (Figure 1).
The reality
These ar no ordinary patients. They h ve travelled far from home to escape war, poverty, and mis-
ery. They have ndured personal odysseys to get here, experienced untold hardships, and suffered
unimaginable privations. Many have survived the loss of their families, torture, and rape. Their jour-
neys over, for the moment at least, they must make their homes in the Calais Jungle. Their new shel-
ters are in many cases mere tarpaulin covers, and their new beds just rugs on the ground. They own
next to nothing. Ther is little for them to do, besides use their ingenuity to cross the English Chan-
nel in search of a better life. They are vuln rabl to xploitation, crime, injury, and disease. Poten-
tially violent clashes with local police, with other ethnic groups resident in the Jungle, or local far
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Ab t act
Background: Guidelines r commend drug treatment for patients with he rt failure with a reduced
ejection fraction (HFrEF), however the evidence for benefit in pati nts with mild disease, such as
most in primary care, is uncertain. Im ortantly, drugs co monly used in h art failure account for
one in seven of emergency dmissions for adverse drug reacti ns.
Aim: To determine to what extent patients included in studies of heart failure treatment with beta-
blockers, angiotensin-converting enzyme (ACE) inhibitors, and aldosterone antagonists were
representative of a typical primary care population with HFrEF in England.
Desig & setti g: Syste atic review of randomised controlled trials (RCTs) f drug treatment in
patients with HFrEF.
Method: MEDLINE, MEDLINE In-Proc ss, EMBASE, and CENTRAL w re search d from inc pti
to March 2015. The characteristics of patie t’s New York Heart Association (NYHA)
classification were c mpared with primary care reference pop lation with HFrEF.
Results: Of the 30 studies included, two had incomplete data. None had a close match (defined as
10% deviation from refer nce study) for NYHA class I disease; 5/28 were a close match for NYHA
cl s II; 5/28 for NYHA class III; and 18/28 for NYHA class IV. In general, pre-existing c rdiovascular
conditions, risk fact rs, and comorbidities wer representative of the reference population.
Conclusion: Patients recruited to studies typically had more severe heart failure than the reference
primary care population. When evidence from sicker patients is generalised to less sick people,
there is increased uncertainty about benefit and also a risk of harm from overtreatment. More
evidence is needed on the effectiveness of treatment of heart failure in asymptomatic patients with
NYHA class I.
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How this fits in
Heart failure is common in primary care and carries a high morbidity and mortality which is associ-
ated with the degree of failure; beta-blockers, ACE inhibitors or angiotensin II receptor blockers
(ARBs), and aldosterone antagonists have all been shown to reduce mortality and morbidity, but
also carry a significant risk of adverse drug reactions. This study shows that patients with heart failure
in primary care tend to have mild heart failure, but the evidence for effectiveness for these drugs
comes from a population with more severe heart failure. More evidence is needed for the effective-
ness of these treatments in populations typical of primary care.
Introduction
HFrEF is a common chronic, debilitating disease which has a prevalence of 0.7% and affects 400 000
adults in the UK.1 The annual cost of heart failure to the NHS is around 2% of its total budget, and
approximately 70% of this total is due to the costs of hospitalisation.2 There is a large variation in
clinical presentation of heart failure, with some patients having no symptoms at the time of diagnosis
whereas others have significant morbidity. The diagnosis is made based on the presence of signs
and symptoms of heart failure and through the use of echocardiography to measure left ventricular
ejection fraction (LVEF).3 An LVEF <40% confirms a diagnosis of HFrEF, which has been extensively
studied in the literature.
Symptoms of heart failure can be graded using the NYHA functional classification into one of four
categories (Box 1).4 In one study of UK primary care patients with HFrEF, 47% had no symptoms
(class I), 36% had mild symptoms (class II), 7% had moderate symptoms (class III), and 10% had
severe symptoms (class IV).5 Mortality rates from heart failure are high; one UK cohort study
reported that 14% (95% confidence interval [CI] = 11% to 18%) of patients died within 6 months of
diagnosis.6 Patients with higher NYHA symptom scores have a worse prognosis, although even
patients with mild heart failure have higher mortality than the general population.7
Several large trials have found a reduction in mortality and hospitalisation in patients with systolic
heart failure following treatment with beta-blockers, ACE inhibitors, and aldosterone
antagonists.8,9 These drugs have also been shown to be cost-effective for the treatment of heart
failure.10 This evidence has led to guideline recommendations adopting these treatments for systolic
heart failure across the world.2,7,11,12 The National Institute for Health and Care Excellence (NICE)
heart failure guideline recommends that all primary care patients with systolic heart failure should be
offered beta-blockers and ACE inhibitors, regardless of NYHA class. This indicator is supported by
evidence generalised from higher risk populations (NYHA classes III–IV), in which there is clear evi-
dence of benefit for beta-blockers and ACE inhibitors, but the evidence of benefit in lower risk pop-
ulations is more equivocal.13,14
The applicability of guideline recommendations for management of diseases (including heart fail-
ure) in primary care has recently been questioned as this research is rarely conducted in representa-
tive populations.13 This question is important in heart failure because the effectiveness of treatment
Box 1. New York Heart Association classes of heart failure.4
Class Patient symptoms
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation,
dyspnoea (shortness of breath).
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue,
palpitation, dyspnoea (shortness of breath).
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue,
palpitation, or dyspnoea.
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any
physical activity is undertaken, discomfort increases.
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may depend on the severity of disease, and beta-blockers and ACE inhibitors carry significant mor-
bidity risk, accounting for approximately one in seven emergency hospital admissions due to adverse
drug reactions.15
The aim of this study was to determine to what extent patients included in studies of heart failure
treatment with beta-blockers, ACE inhibitors, and aldosterone antagonists were representative of
the NYHA class and other characteristics of a typical primary care population with heart failure in
England.
Method
A literature search was undertaken to identify RCTs of systolic heart failure drugs. MEDLINE, MED-
LINE In-Process, EMBASE, and CENTRAL were searched from inception to March 2015. The search
strategy for MEDLINE (further information available from the authors on request) was modified for
other databases. Titles and abstracts were screened by two authors independently, according to the
following pre-specified inclusion and exclusion criteria.
Inclusion criteria were RCTs which included patients with HFrEF. Intervention drugs included ACE
inhibitors, beta-blockers, ARBs, and aldosterone antagonists, such as spironolactone and eplener-
one. There were no language restrictions. Exclusion criteria were studies with a follow-up of <6
weeks duration, those comprising a single-dose regimen, and studies not judged to be generalisable
to a primary care population (such as one study of patients on dialysis). Disagreements were
resolved through discussion or by a third researcher, and full text articles were retrieved for each
abstract meeting the inclusion criteria.
Data were extracted from each included study into a template which included study design, inter-
vention, inclusion and exclusion criteria, baseline characteristics, primary outcome, and mortality
data. Data extraction was checked by a second researcher and any disagreements were resolved
through discussion or by a third researcher. Authors were contacted for individual-level data. No
authors shared individual-level data and the difficulties accessing these data have been described
elsewhere.16 Study exclusion was guided by pre-defined exclusion criteria as described.
Data was used from the largest study on the prevalence of heart failure in the UK, that is the
Echocardiographic Heart Study of England Screening (EHES) study.5 This study randomly selected a
large population of 6286 people aged 45 years and, of the five studies of heart failure prevalence
identified, was the best fit to an English population.17–19 The EHES study had a high participation
rate of 63% (3960 patients) and wide geographical spread of populations which was representative
of inner-city, urban, suburban, and rural communities. The EHES study was used as the reference
population throughout this study.
For each study, the NYHA class, baseline cardiovascular risk factors, baseline cardiovascular
comorbidities, and use of heart failure drugs were analysed. These outcomes were compared
between the reference study and each extracted study. Each patient-specific variable was compared
to the reference study in terms of prevalence or frequency of use. To allow quantification of similarity
between the selected study population and the reference study population, the percentage devia-
tion was assessed and allocated as being a close match, fair match, or poor match. If the extracted
study population had a 10% deviation from the reference study, it was termed as a close match; if
the deviation was 11–20%, it was termed a fair match; and if the deviation was >20%, it was termed
a poor match These parameters were set out a priori. For example, if a study reported 10% class I,
25% class II, 40% class III, and 25% class IV, to assess close match a 10% absolute deviation was
applied (that is, 0–20, 15–35, 30–50, and 15–35% respectively) and compared it to classes in the ref-
erence population (47, 36, 7, and 10% respectively). This worked example is shown in Table 1 (fur-
ther information available from the authors on request).
Results
Literature searching identified 6785 studies, 4433 after de-duplication (Figure 1). Thirty RCTs met
the inclusion criteria, representing 43 454 patients with HFrEF. Characteristics of included studies
are shown in Table 2. Of the included studies, 13 investigated beta-blockers, 8 ACE inhibitors, 6
ARBs, and 4 spironolactone. One study compared ACE inhibitors and ARBs (ELITE I, 2000). In the 30
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extrapolated studies, sample size ranged from 59–5010 participants. Follow-up ranged from 3–73
months.
Characteristics of the reference population are shown in Table 3. The overall mean age was 69
years, and 81% of the reference population was male. Most patients had NYHA class I (47%) and
only 17% of patients had class III or IV.
Table 1 Example assessment of an extracted paper compared to the reference population
Class I Class II Class III Class IV
Reference population, % 47 36 7 10
Extracted study, % 10 25 40 25
Extracted study with 10% deviation, % 0–20 15–35 30–50 15–35
Closeness of match, % >20 11–20 >20 11–20
Closeness of match, label Poor Fair Poor Fair
Figure 1. PRISMA diagram.
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NYHA class
Table 4 shows heart failure RCTs compared to the reference population, stratified by NYHA class.
Of the 30 studies, 28 had complete data on NYHA classes. None of the studies had a close match
for NYHA class I disease, 3/28 (11%) displayed a fair match, and 25/28 (89%) a poor match. For
NYHA class II 5/28 (18%) studies has a close match, 9/28 (32%) a fair match, and 14/28 (50%) a poor
match. For NYHA class III, 5/28 (18%) displayed a close match, 3/28 (11%) a fair match, and 20/28
(71%) a poor match. For NYHA class IV, 3/28 (11%) displayed a fair match, and 18/28 (64%) dis-
played a close match and 7/28 (25%) had a poor match.
Baseline cardiovascular risk factors
Cardiovascular risk factors were largely representative of the reference population (further informa-
tion available from the authors on request). Of the 30 studies, 25 (83%) had a close match to the age
of the reference population, which was a mean of 69 years. Nineteen studies (63%), had a close
match with the sex characteristics of the reference population, which was 81% male. The majority of
extracted studies (20/30, 67%), did not present ethnicity data. Of those that did, 7/10 (70%) had a
close match and 3/10 (30%) had a poor match with the reference population, which was 97% white.
Of the 30 extracted studies, 23 (77%) did not present smoking status data. Of the seven that did,
one (14%) had a fair match and six (86%) a poor match to the reference population, 69% of whom
were smokers. A family history of premature myocardial infarction was not reported in any of the
studies.
Baseline cardiovascular comorbidities
The majority of the studies (23/30, 77%), reported the presence of pre-existing angina but 13/30
(43%) studies did not report the presence of previous myocardial infarction, pre-existing hyperten-
sion, or diabetes mellitus (further information available from the authors on request). In general, pre-
existing cardiovascular conditions recorded in the extracted studies were representative of the refer-
ence population. When comparing for the presence of pre-existing myocardial infarction, 10/17
(59%) of the extracted studies had a close match, 6/17 (35%) had a fair match, and 1/17 (6%) had a
poor match to the reference population, which reported a prevalence of 53%. A similar trend was
noted for hypertension, for which 7/17 (41%) of the extracted studies had a close match, 3/17 (18%)
had a fair match, and 7/17 (41%) had a poor match to the reference population, which had a
reported prevalence of 39%.
For diabetes mellitus, 7/17 (41%) of the extracted studies had a close match, 6/17 (35%) had a
fair match, and 4/17 (24%) had a poor match to the reference population (reported prevalence,
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had a close match, 3/7 (43%) had a fair match, and 1/7 (14%) had a poor match to the reference
population (reference population reported prevalence, 36%).
Use of heart failure drugs
The use of important heart failure drugs varied significantly across the analysed studies (further infor-
mation available from the authors on request). Of the 30 studies, 20 (67%) did not report data on
the use of aspirin. Of the remainder, 5/10 (50%) had a close match, 4/10 (40%) a fair match, and 1/
10 (10%) had a poor match to the reference population, of whom 53% took regular aspirin.
Of the 30 extracted studies, 22 (73%) did not report data on the use of calcium channel blockers
(CCBs). Of the remaining eight, four (50%) had a close match, and four (50%) had a fair match to the
reference population, which reported CCB usage in 21%.
A large proportion of the extracted studies investigated beta-blockers and ACE inhibitors
directly, and therefore were not assessed for prevalence of use of these therapies compared to the
Table 3 Summary of the ejection fraction <40% cohort for the reference population
Characteristic Total (n = 72), n (%)
Mean age, years (SD) 69 (9)
Female 14 (19)
Male 58 (81)
Ever smoked 50 (69)
Non-white 2 (3)
Any electrocardiogram abnormality 2 (3)
Mean height, metres (SD) 1.71 (0.09)
Mean weight, kg (SD) 80.8 (14.6)
Mean heart rate, beats per min (SD) 77.3 (17.8)
Mean forced expiratory volume at 1 second, litres (SD) 2.11 (0.76)
Mean forced vital capacity, litres (SD) 2.55 (0.85)
Mean systolic blood pressure, mmHg (SD) 148.4 (21.1)
Mean diastolic blood pressure, mmHg (SD) 87.1 (12.3)










Family myocardial ischaemia (age <65 years) 25 (35)
Medication taken
ACE inhibitors 19 (26)
Diuretics 26 (36)
Beta-blockers 9 (13)
Calcium antagonists 15 (21)
Aspirin 38 (53)
Digoxin 5 (7)
SD = standard deviation.
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reference population. Of the 18 studies which did not study beta-blockers, 11 (61%) did report data
on the proportion of patients using beta-blockers, and only three (27%) of these 11 had a close
match to the reference population, which reported a frequency of 13%.
Of the 22 studies that did not directly study ACE inhibitors, eight (36%) did not report prevalence
of use. Therefore only 14 (47%) of the 30 total extracted studies could be assessed for ACE inhibi-
tors, all of which had a poor match to the reference population, which reported a frequency of 26%.
Eleven (37%) studies did not report data on the proportion of patients using digoxin. Of the
remaining 19, two (11%) had a close match, two (11%) had a fair match, and 15 (79%) had a poor
match to the reference population, which had a reported frequency of 7%.
Spironolactone and eplenerone were the study drug in 4/30 studies and these were therefore not
assessed for similarity to the reference population. Of the remaining 26 studies that did not directly
Table 4. NYHA classification in heart failure RCTs compared to the reference population.
NYHA class5
Heart failure RCTs N Ia, % IIb, % IIIc, % IVd, %
SOLVD 1992 4228 11–20 <10 <10 <10
Munich 1991 170 11–20 11–20 11–20 <10
Borghi 2013 175 11–20 11–20 11–20 <10
US Carvedilol 1996 1094 >20 <10 >20 <10
Liu 2014 154 >20 <10 >20 <10
CHARM Added 2003 2548 >20 <10 >20 <10
MERIT-HF 1999 3991 >20 <10 >20 <10
Zannad 1998 254 >20 >20 <10 <10
CELICARD 2000 124 >20 11–20 >20 <10
CHARM Alternative 2003 2028 >20 11–20 >20 <10
SENIORS 2005 2128 >20 11–20 >20 <10
SOLVD 1991 2569 >20 11–20 >20 <10
COMET 2003 3029 >20 11–20 >20 <10
Cicoira 2002 106 e e e e
CARNEBI 2013 183 >20 >20 <10 >20
MAIN CHF II 2014 59 >20 >20 <10 >20
Colucci 1996 366 >20 >20 <10 >20
Zannad 2011 2737 >20 >20 >20 <10
Sturm 2000 100 >20 >20 >20 <10
Cohn 2001 5010 >20 >20 >20 <10
CIBIS 1994 641 >20 >20 >20 <10
CIBIS 1999 2647 >20 >20 >20 <10
ELITE II 2000 3152 >20 11–20 >20 >20
Kum 2008 100 >20 11–20 >20 >20
Rieger 1999 844 >20 >20 11–20 >20
BEST 2003 226 >20 >20 >20 >20
Dalla-Volta 1999 179 >20 >20 >20 >20
AREA-CHF 2009 382 >20 >20 >20 >20
Pitt 1999 1663 >20 >20 >20 >20
Yodfat 1991 84 e e e e
a47% of reference population. b36% of reference poulation. c7% of reference population. d10% of reference population. eInsufficient information to calculate
deviation. RCT = randomised controlled trial. NYHA = New York Heart Association.
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investigate these agents, 10 (38%) did not report prevalence of use data. As such, only 16/30 (53%)
studies could be assessed for spironolactone and eplenerone use, all of which had a poor match to
the reference population, which had a reported frequency of 36%.
The authors of this study examined the six studies that were a close match for NYHA class II par-
ticipants for evidence of benefit for this class. Only one study (MERIT-HF) reported outcomes by
NYHA class II,48 the remaining studies reported pooled outcomes for all NYHA classes. MERIT-HF
reported no significant mortality reduction, but a reduction in two out of four secondary outcomes
(development of congestive heart failure [CHF] and hospitalisations).
Discussion
Summary
Of the reference population representing a primary care population with HFrEF, 83% had mild symp-
toms in NYHA class I and II, however none of the 30 studies were matched closely with NYHA class
I, and only 5/28 (18%) studies were a close match with NYHA class II symptoms. For patient charac-
teristics of age, sex, ethnicity, previous myocardial infarction, hypertension, diabetes, and angina,
>40% studies were closely matched to the reference population. For patient characteristics of smok-
ing status; family history of premature heart disease; and the use of beta-blockers, ACE inhibitors,
and the aldosterone antagonists spironolactone and eplenerone, <30% of studies were closely
matched to the reference population. In this way, this systematic review has shown that these studies
are not typically representative of the primary care population in England, with patients with more
severe heart failure being overrepresented.
Strengths and limitations
This study is the first systematic review to determine whether the types of patients included in stud-
ies of treatments for HFrEF were representative of a typical primary care population with HFrEF in
England. A large study was used as the reference population,5 which randomly selected and
screened the population for HFrEF, and the systematic review method of the present study was
robust. While this reference study was published 15 years ago, and the characteristics of the primary
care population and treatments have changed, it is closer to the time when the included RCTs were
undertaken. The present authors had initially intended to obtain individual-level data for each NYHA
class from each of the 30 identified studies, however, there were obstacles in terms of non-disclosure
of further information from these studies’ authors, who either failed to reply to repeated attempts to
make contact or were unwilling for the present authors to access their trial data.16 There may be
some overlap between classes, such as class I and II, which may have led to misclassification in either
the reference study or the included trials. Only trials which recruited patients with heart failure were
included, and there is a possibility that some trials with a subgroup of patients with heart failure may
not have been identified.
Comparison with existing literature
This study concurs with the findings of Steel et al, who reported that out of 48 studies cited in the
National Institute for Health and Care Excellence guidance on heart failure treatment, 43 (90%) were
studies of uncertain relevance to patients in primary care.14 These findings are particularly important
as there is evidence that heart failure treatments may be less effective in patients with less severe
heart failure,16,49,50 and these drugs do account for significant morbidity.
Implications for research and practice
The underrepresentation of patients with HFrEF and mild or absent symptoms in clinical trials has
implications for GPs, who should weigh the potential benefits of initiating treatment in those with
absent or mild symptoms against the risks of an adverse drug reaction. These risks are significant,
although all degrees of heart failure have raised mortality and morbidity. By extrapolating data from
studies of patients with more severe disease, patients and clinicians may misinterpret the potential
benefits and risks. It is important that the risks and benefits are stratified by NYHA disease class.
More studies are needed using individual patient data analysis by heart failure severity, as most
of the outcomes in the current studies were not reported by NYHA class. This should be
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complemented by observational studies using, for example, the Clinical Practice Research Datalink
dataset which primarily recruit from primary rather than secondary care.
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